Retinitis Pigmentosa Stem Cell Treatment

Stem Cell Treatmtent for Retinitis Pigmentosa

stem cell treatment for retinitis pigmentosa

Stem Cell Treatment for Retinitis Pigmentosa

Retinitis Pigmentosa treatments using stem cells is now an option...

Retinitis pigmentosa is a group of genetic eye conditions that leads to incurable blindness. In the progression of symptoms for Retinitis pigmentosa, night blindness generally precedes tunnel vision by years or even decades. Many people with Retinitis pigmentosa do not become legally blind until their 40s or 50s and retain some sight all their lives. Others go completely blind from Retinitis pigmentosa, in some cases as early as childhood. Progression of Retinitis pigmentosa is different in each case.

Retinitis pigmentosa is a type of progressive retinal dystrophy, a group of inherited disorders in which abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium of the retina lead to progressive visual loss. Affected individuals first experience defective dark adaptation or nyctalopia (night blindness), followed by reduction of the peripheral visual field (known as tunnel vision) and, sometimes, loss of central vision late in the course of the disease.

At SIRM, our goal is to get you seeing again. Let us help you!

Stem Cell Treatment for Retinitis Pigmentosa

Streaming NIH database and search results:

Related Articles Generation of a human iPS cell line from a patient with retinitis pigmentosa due to EYS mutation. Stem Cell Res. 2018 12;33:251-254 Authors: Calado SM, Garcia-Delgado AB, De la Cerda B, Ponte-Zuñiga B, Bhattacharya SS, Díaz-Corrales FJ Abstract Retinitis pigmentosa (RP) is an inherited retinal degenerative disease. Mutations in EYS have been associated with autosomal recessive RP. The human iPS cell line, CABi002-A, derived from peripheral blood mononuclear cells from a patient carrying a heterozygous double mutation in EYS gene was generated by non-integrative reprogramming technology, using hOCT3/4, hSOX2, hc-MYC and hKLF4 reprogramming factors. Pluripotency and differentiation capacity were assessed by immunocytochemistry and RT-PCR. This iPSC line can be further differentiated towards the affected cells to understand the pathophysiology of the disease and test new therapeutic strategies. PMID: 30471616 [PubMed - indexed for MEDLINE]

Quick Contact Form